January 27, 2017
Eisai said on January 25 that its cancer drug Lenvima (lenvatinib) demonstrated non-inferiority to Nexavar (sorafenib) in overall survival (OS) as a first-line treatment for patients with hepatocellular carcinoma (HCC), the most common type of liver cancer, in a PIII...read more